Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 17, 2009, Pages 5004-5008

  Worm, Karin ^a   Weaver, Damian G ^a   Green, Rosalyn C ^a   Saeui, Christopher T ^a   Dulay, Doreen Marie S ^a   Barker, William M ^a   Cassel, Joel A ^a   Stabley, Gabriel J ^a   DeHaven, Robert N ^a   LaBuda, Christopher J ^a   Koblish, Michael ^a   Brogdon, Bernice L ^a   Smith, Steven A ^a   Dolle, Roland E ^a  

^a ADOLOR CORPORATION   (United States)

Author keywords

Antiallodynic activity; Cannabinoid CB2 receptor agonist; Metabolic stability; Selectivity; Structure activity relationship

Indexed keywords

BENZAMIDE DERIVATIVE; CANNABINOID 2 RECEPTOR; N [3 (MORPHOLINOMETHYL)PHENYL]AMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; NONHUMAN; POSTOPERATIVE PAIN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DISCOVERY; HUMANS; PAIN, POSTOPERATIVE; RATS; RECEPTOR, CANNABINOID, CB2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

RODENTIA;

EID: 68349133322     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.057     Document Type: Article

References (30)

1. Farquhar-Smith W.P. Pain Rev. 9 (2002) 41
2. Klein T.W. Nat. Rev. Immun. 5 (2005) 400
3. Walter L., and Stella N. Br. J. Pharmacol. 141 (2004) 775
4. Smith P.F. Curr. Opin. Invest. Drugs 6 (2005) 680
5. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. Pharmacol. Rev. 54 (2002) 161
6. Pertwee R.G. Prog. Neurobiol. 63 (2001) 569
7. Mackie K. J. Neuroendocrin. 20 (2008) 10
8. Rice A.S. Curr. Opin. Invest. Drugs 2 (2001) 399
9. Worm K., et al. Abstracts of Papers (2007), 234th National Meeting of the American Chemical Society, Boston, MA August 19-23
10. MEDI 030:. Liu X., Chen C., and Smith B.J. J. Pharmacol. Exp. Ther. 325 (2008) 349
11. Kunos G., Osei-Hyiaman D., Batkai S., Sharkey K.A., and Makriyannis A. Trends Pharmacol. Sci. 30 (2009) 1
12. Malan T.P., et al. Curr. Opin. Pharmacol. 3 (2003) 62
13. Ashton J.C., Wright J.L., McPartland J.M., and Tyndall J.D.A. Curr. Med. Chem. 15 (2008) 1428
14. Childers W.E., Gilbert A.M., Kennedy J.D., and Whiteside G.T. Exp. Opin. Ther. Patents 18 (2008) 1027
15. Guindon J., and Hohmann A.G. Br. J. Pharmacol. 153 (2008) 319
16. Marriott K.-S.C., and Huffman J.W. Curr. Top. Med. Chem. 8 (2008) 187
17. Hoegenauer E.K. Exp. Opin. Ther. Patents 17 (2007) 1457
18. Pasquini S., Botta L., Semeraro T., Mugnaini C., Ligresti A., Palazzo E., Maione S., Di Marzo V., and Corelli F. J. Med. Chem. 51 (2008) 5075
19. Frost J.M., Dart M.J., Tietje K.R., Garrison T.R., Grayson G.K., Daza A.V., El-Kouhen O.F., Miller L.N., Li L., Yao B.B., Hsieh G.C., Pai M., Zhu C.Z., Chandran P., and Meyer M.D. J. Med. Chem. 51 (2008) 1904
20. Kai H., Morioka Y., Koriyama Y., Okamoto K., Hasegawa Y., Hattori M., Koike K., Chiba H., Shinohara S., Iwamoto Y., Takahashi K., and Tanimoto N. Bioorg. Med. Chem. Lett. 18 (2008) 6444
21. Diaz P., Xu J., Astruc-Diaz F., Pan H.-M., Brown D.L., and Naguib M. J. Med. Chem. 51 (2008) 4932
22. Cheng Y., Albrecht B.K., Brown J., Buchanan J.L., Buckner W.H., DiMauro E.F., Emkey R., Fremeau R.T., Harmange J.-C., Hoffman B.J., Huang L., Huang M., Lee J.H., Lin F.-F., Martin M.W., Nguyen H.Q., Patel V.F., Tomlinson S.A., White R.D., Xia X., and Hitchcock S.A. J. Med. Chem. 51 (2008) 5019
23. Ohta H., Ishizaka T., Tatsuzuki M., Yoshinaga M., Iida I., Yamaguchi T., Tomishima Y., Futaki N., Toda Y., and Saito S. Bioorg. Med. Chem. 16 (2008) 1111
24. Worm K., Zhou Q.J., Saeui C.T., Green R.C., Cassel J.A., Stabley G.J., DeHaven R.N., Conway-James N., LaBuda C.J., Koblish M., Little P.J., and Dolle R.E. Bioorg. Med. Chem. Lett. 18 (2008) 2830
25. Goodman A.J., Ajello C.W., Worm K., Le Bourdonnec B., Savolainen M.A., O'Hare H., Cassel J.A., Stabley G.J., DeHaven R.N., LaBuda C.J., Koblish M., Little P.J., Brogdon B.L., Smith S.A., and Dolle R.E. Bioorg. Med. Chem. Lett. 19 (2009) 309
26. Binding assays were performed by modification of the method of:. Pinto J.C., Potie F., Rice K.C., Boring D., Johnson M.R., Evans D.M., Wilken G.H., Cantrell C.H., and Howlett A. Mol. Pharmacol. 46 (1994) 516
27. 35S]GTPγS binding method is a major modification of the method by. Selley D.E., Stark S., Sim L.J., and Childers S.R. Life Sci. 59 (1996) 659 Additional details are given in Ref. 9
28. 2): C, 48.17; H, 5.17; N, 6.24. Found: C, 48.10; H, 5.25; N, 6.09.
29. Obach S.R. Drug Metab. Dispos. 27 (1999) 1350
30. Brennan T.J., Vandermeulen E.P., and Gebhart G.F. Pain 64 (1996) 493